PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab. (March 2016)

• Record Type: Journal Article
• Authors: Dahagam, Chanukya; Goud, Aditya; Abdelqader, Abdelhai; Hendrani, Aditya; Feinstein, Matthew J; Qamar, Arman; Joshi, Parag H; Swiger, Kristopher J; Byrne, Kathleen; Quispe, Renato; Jones, Steven R; Blumenthal, Roger S; Martin, Seth S
• Is Part Of: Future cardiology. Volume 12:Number 2(2016)
• Page Start: 149
• Page End: 157
• Publication Date: 2016-03
• Subjects: alirocumab -- evolocumab -- LDL -- monoclonal antibodies -- PCSK9 inhibitors -- statin intolerance; Cardiology -- Research -- Periodicals; 616.12005
• DOI: 10.2217/fca.15.88
• Languages: English
• ISSNs: 1479-6678

Abstract

In this review, we examine alirocumab (Praluent ® ), a monoclonal antibody to PCSK9 and its role in reducing LDL-C levels. By comparing the results of various studies and trials we discuss the efficacy and safety of alirocumab. We aim to guide clinicians of the role of alirocumab in clinical practice. Overall, PCSK9 inhibitors are promising new agents in further reducing LDL-C levels in addition to diet and maximally tolerated statin therapy. Long-term outcome studies are currently ongoing and will further delineate the role of PCSK9 inhibitors.